Diabetes

December 12, 2018

A probiotic way to ameliorate Diabetes Mellitus: Probiotic VSL#3 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 12/December/2018, 7.06 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
December 10, 2018

 Erythropoietin (EPO)-based therapy for body weight control, energy homeostasis and TIIDM: Erythropoietin (EPO) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 11/December/2018, 5.00 am

Introduction: What they say  A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]
December 9, 2018

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Memantine (brand name: Axura, Ebixa, Namenda),  an anti-alzheimer’s drug,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/December/2018, 11.58 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
December 9, 2018

Repurposing the anti-psychotic medication into an anti-diabetic medication: Amisulpride (brand name: Solian), an antipsychotic medication used to treat schizophrenia, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 9/December/2018, 11.36 pm

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at […]